NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.
Most people with type 2 diabetes should be offered SGLT-2 inhibitors much earlier in their treatment, final NICE guidance has ...
People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...
Statistics indicate that type 2 diabetes (T2D) affects approximately 14% of the global population. This is significant ...
The usefulness and relevance of diabetes clinical guidelines are beyond doubt. Their use is widespread among internal medicine clinicians, though they have a weakness: “The most relevant information ...
The Food and Drug Administration recently approved Belgium-based Janssen Pharmaceuticals’ drug Invokamet XR for first-line use to improve glycemic control in diabetic adults when paired with diet and ...
A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new ...
A large registry study in young people with type 1 diabetes found that hybrid closed-loop systems were linked to slightly better HbA1c and more time in the target glucose range than open-loop pump ...
A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results